The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above. A control group in younger adults aged 18 to 40 years was included.
This is a study to demonstrate the superiority of the immune response of adjuvanted influenza vaccine induced in an adult population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Enrollment
3,350
To demonstrate that the immune response induced by the adjuvanted influenza vaccine in the elderly is superior to that induced by Fluarix, for each vaccine strain
To evaluate in all subjects, the safety, the humoral response and the cell-mediated immune (CMI) response of the adjuvanted influenza vaccine and Fluarix
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Coral Gables, Florida, United States
GSK Investigational Site
Milford, Massachusetts, United States
GSK Investigational Site
Chaska, Minnesota, United States
GSK Investigational Site
Somers Point, New Jersey, United States
GSK Investigational Site
Poughkeepsie, New York, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Carnegie, Pennsylvania, United States
GSK Investigational Site
Erie, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
...and 20 more locations